Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

被引：6

作者：

Gurbuz, Mustafa ^{[1
]}

Kutlu, Yasin ^{[2
]}

Akkus, Erman ^{[3
]}

Koksoy, Elif Berna ^{[1
]}

Kose, Naziyet ^{[4
]}

Oven, Bala Basak ^{[5
]}

Uluc, Basak Oyan ^{[6
]}

Demiray, Atike Gokcen ^{[7
]}

Erdem, Dilek ^{[8
]}

Demir, Bilgin ^{[9
]}

Turhal, Nazim Serdar ^{[10
]}

Uskent, Necdet ^{[10
]}

Akbas, Sinem ^{[11
]}

Selcukbiricik, Fatih ^{[11
]}

Inal, Ali ^{[12
]}

Bilici, Ahmet ^{[2
]}

Olmez, Omer Fatih ^{[2
]}

Cabuk, Devrim ^{[13
]}

Unal, Caglar ^{[14
]}

Hizal, Mutlu ^{[15
]}

Sendur, Mehmet Ali Nahit ^{[15
]}

Korkmaz, Mustafa ^{[16
]}

Karadurmus, Nuri ^{[17
]}

Erturk, Ismail ^{[17
]}

Goksu, Sema Sezgin ^{[18
]}

Tatli, Ali Murat ^{[18
]}

Guven, Deniz Can ^{[19
]}

Kilickap, Saadettin ^{[20
]}

Paksoy, Nail ^{[21
]}

Aydiner, Adnan ^{[21
]}

Cinkir, Havva Yesil ^{[22
]}

Ozkul, Ozlem ^{[23
]}

Ozturk, Akin ^{[24
]}

Balli, Sevinc ^{[1
]}

Kemal, Yasemin ^{[8
]}

Erdogan, Atike Pinar ^{[25
]}

Er, Ozlem ^{[26
]}

Yumuk, Perran Fulden ^{[11
]}

Demirkazik, Ahmet ^{[1
]}

机构：

[1] Ankara Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[2] Istanbul Medipol Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[3] Ankara Univ, Fac Med, Dept Internal Med, Ankara, Turkey

[4] Mem Ankara Hosp, Dept Med Oncol, Ankara, Turkey

[5] Bahcesehir Univ, Fac Med, Dept Med Oncol, Gortepe Med Pk Hosp, Istanbul, Turkey

[6] Acibadem Altunizade Hosp, Dept Med Oncol, Istanbul, Turkey

[7] Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkey

[8] Samsun Med Pk Hosp, Dept Med Oncol, Samsun, Turkey

[9] Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkey

[10] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkey

[11] Koc Univ Hosp, Dept Med Oncol, Istanbul, Turkey

[12] Mersin City Hosp, Dept Med Oncol, Mersin, Turkey

[13] Kocaeli Univ, Fac Med, Dept Med Oncol, Kocaeli, Turkey

[14] Gayrettepe Florence Nightingale Hosp, Dept Med Oncol, Istanbul, Turkey

[15] Yildirim Beyazit Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[16] Necmettin Erbakan Univ, Meram Fac Med, Dept Med Oncol, Konya, Turkey

[17] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkey

[18] Akdeniz Univ, Fac Med, Dept Med Oncol, Antalya, Turkey

[19] Hacettepe Univ, Fac Med, Dept Med Oncol, Ankara, Turkey

[20] Istinye Univ, Liv Ankara Hosp, Fac Med, Dept Med Oncol, Ankara, Turkey

[21] Istanbul Univ, Fac Med, Dept Med Oncol, Istanbul, Turkey

[22] Gaziantep Univ, Fac Med, Dept Med Oncol, Gaziantep, Turkey

[23] Bagcilar Training & Res Hosp, Dept Med Oncol, Istanbul, Turkey

[24] Sureyyapasa Chest Dis & Thorac Surg Training & Re, Dept Med Oncol, Istanbul, Turkey

[25] Manisa Celal Bayar Univ, Dept Med Oncol, Fac Med, Manisa, Turkey

[26] Maslak Acibadem Hosp, Dept Med Oncol, Istanbul, Turkey

来源：

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2022年 / 148卷 / 12期

关键词：

Atezolizumab; Small cell lung cancer; Immunotherapy; PD-L1; ETOPOSIDE; PLATINUM;

D O I：

10.1007/s00432-022-04087-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Atezolizumab has been shown to be effective and safe in randomized trial in the first-line treatment of extensive-stage small cell lung cancer (SCLC). However, there are limited real-life data on atezolizumab. In this study, we aimed to determine the real-life efficacy and safety of atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage SCLC. Methods This trial is a retrospective multicenter study of the Turkish Oncology Group, which included extensive-stage SCLC patients who received atezolizumab combined with chemotherapy in a first-line treatment. The characteristics of the patients, treatment and response rates, and PFS and OS are presented. Factors associated with PFS and OS were analyzed by univariate and multivariate analysis. Results A total of 213 patients at the 30 oncology centers were included. The median number of chemotherapy cycle was 5 (1-8) and atezolizumab cycle was 7 (1-32). After median 11.9 months of follow-up, median PFS and OS was 6.8 months (95%CI 5.7-7.8), and 11.9 months (95%CI 11-12.7), respectively. The ORR was 61.9%. ECOG-PS (p = 0.002) and number of metastatic sites (p = 0.001) were associated with PFS and pack-year of smoking (p = 0.05), while ECOG-PS (p = 0.03) and number of metastatic sites (p = 0.001) were associated with OS. Hematological side effects were common and toxicities were manageable. Conclusion This real-life data confirm the efficacy and safety of atezolizumab in combination with chemotherapy in first-line treatment of extensive-stage SCLC.

引用

页码：3547 / 3555

页数：9

共 50 条

[41] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
Li, Ling-Yu
Wang, Hong
Chen, Xiao
Li, Wen-Qian
Cui, Jiu-Wei
CHINESE MEDICAL JOURNAL, 2019, 132 (23) : 2790 - 2794
[42] Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center
Li, Yuying
Jing, Wang
Jing, Xuquan
Sun, Yulan
Tang, Xiaoyong
Guo, Jun
Zhang, Yan
Zhu, Hui
DISCOVER ONCOLOGY, 2023, 14 (01)
[43] Efficacy and toxicity profile of first-line treatment for extensive-stage small cell lung cancer: A Bayesian network meta-analysis
Lin, Guo
Yao, Zhuoran
Kang, Kai
Wang, Hui
Luo, Ren
Lu, You
CANCER MEDICINE, 2023, 12 (09): : 10230 - 10242
[44] Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide
Liu, Stephen, V
Mok, Tony S. K.
Nabet, Barzin Y.
Mansfield, Aaron S.
De Boer, Richard
Losonczy, Gyorgy
Sugawara, Shunichi
Dziadziuszko, Rafal
Krzakowski, Maciej
Smolin, Alexey
Hochmair, Maximilian J.
Garassino, Marina C.
Gay, Carl M.
Heymach, John, V
Byers, Lauren A.
Lam, Sivuonthanh
Cardona, Andres
Morris, Stefanie
Adler, Leah
Shames, David S.
Reck, Martin
LUNG CANCER, 2023, 186
[45] Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis
Zhang, Tianming
Li, Wenjun
Diwu, Danbei
Chen, Lijun
Chen, Xi
Wang, Hong
FRONTIERS IN IMMUNOLOGY, 2023, 14
[46] Efficacy and safety analysis of atezolizumab continuation beyond progression in extensive-stage small cell lung cancer
Shi, Wenhao
Bao, Xiaohui
Xiong, Jin
Wu, Yanqiao
Sun, Jianguo
Xu, Zhi
Li, Dairong
Wei, Yang
Ge, Jun
Ren, Biyong
Jiang, Yu
Wang, Kaijin
Huang, Yusheng
Yang, Zhenzhou
Peng, Yuan
CLINICAL AND EXPERIMENTAL MEDICINE, 2025, 25 (01)
[47] Efficacy of EP chemotherapy followed by IP chemotherapy combined with radiotherapy in the treatment of extensive-stage small-cell lung cancer
Kiang, Shiyang
Ou, Chaopeng
Xue, Ruifeng
Zeng, Weian
Huang, Jingxiu
Zhang, Yingjun
Chen, Dongtai
Lai, Jielan
JOURNAL OF BUON, 2021, 26 (02): : 306 - 312
[48] Atezolizumab-induced subacute cerebellar ataxia in a patient with extensive-stage small cell lung cancer
Chen, Chun-Chia
Tseng, Kuan-Hua
Lai, Kuan-Lin
Chiang, Chi-Lu
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[49] Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: a meta-analysis based on mixed-effect models
Zheng, Jianqing
Deng, Yujie
Huang, Bifen
Chen, Xiaohui
FRONTIERS IN MEDICINE, 2023, 10
[50] Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial☆
Lee, Siow Ming
Hewish, Madeleine
Ahmed, Samreen
Papadatos-Pastos, Dionysis
Karapanagiotou, Eleni
Blackhall, Fiona
Ford, Amy
Young, Robin
Garcia, Angel
Arora, Arvind
Hollingdale, Abigail
Ahmad, Tanya
Forster, Martin
Greystoke, Alastair
Bremner, Fion
Rudd, Robin
Farrelly, Laura
Vaja, Simran
Hackshaw, Allan
EUROPEAN JOURNAL OF CANCER, 2025, 215

← 1 2 3 4 5 →